Vanucizumab  (Synonyms: Anti-Human VEGFA Recombinant Antibody; RO5520985)

Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects^[1].

IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover

Human IgG1 kappa, Isotype Control

Human

ANG2 & VEGFA

Vanucizumab (20 mg/kg; i.p.; once weekly; for 6 weeks) shows tumor growth inhibition and induces tumor stasis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

285  [NCBI] & 7422  [NCBI]

Q9UID3 & P15692

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.89 kDa

1448221-05-3

Liquid

Colorless to light yellow

[Vanucizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover

• 
  Immobilized Human VEGFA, His Tag can bind Vanucizumab. The EC₅₀ for this effect is 4.575 ng/mL.
• 
  Immobilized Human ANGPT2, His Tag can bind Vanucizumab. The EC₅₀ for this effect is 78.70 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ HeLa cells with Vanucizumab (HY-P99330, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.

• [1]. Manuel Hidalgo, et al. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 Apr 1;24(7):1536-1545.  [Content Brief]

  [2]. Wolfgang Schaefer, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92.  [Content Brief]